Pharmacy Briefing: January 2020

Pharmacy Briefing is a monthly summary of select U.S. Food and Drug Administration (FDA) approvals and launches, treatment guidelines and research updates, and other newsworthy events that have the potential to impact commercial drug utilization or costs.

Highlights

  • Express Scripts and Prime Therapeutics announce three-year collaboration
  • Department of Justice files lawsuit against Omnicare, alleges fraudulent billing practices using invalid prescriptions
  • OptumRx acquires specialty pharmacy Diplomat for $300 million
  • Louisiana Department of Health reports positive results from “Netflix model” pricing of Hepatitis C drugs

FDA Approvals and Launches

  • Vascepa (icosapent ethyl) receives additional indication to reduce risk of cardiovascular (CV) events in people with elevated triglyceride levels and either established CV disease or type 2 diabetes and two or more CV risk factors.
  • Mylan launches Ogivri (trastuzumab-dkst), the second available biosimilar to Herceptin (trastuzumab).
  • Toujeo (insulin glargine) receives expanded approval to treat children as young as 6 years of age with Type 1 diabetes.
  • Xeljanz XR (tofacitinib) is approved as a once-daily treatment for ulcerative colitis. 
  • PADCEV (enfortumab vedotin-efjv) is approved for the treatment of locally advanced or metastatic urothelial cancer.
  • Arazlo (tazarotene) lotion is approved to treat acne vulgaris.
  • Ubrelvy (ubrogepant) is approved for the acute treatment of migraine.

News

Express Scripts and Prime Therapeutics announce three-year collaboration

  • Express Scripts will provide Prime with retail pharmacy network and pharmaceutical manufacturer contracting services.
  • Prime will continue supplying PBM services to its clients and customers.

Read more

Department of Justice files lawsuit against Omnicare, alleges fraudulent billing practices using invalid prescriptions

  • The CVS-affiliated long-term care pharmacy is accused of failing to obtain new prescriptions after existing prescriptions had expired or run out of refills, electing to instead re-use invalid existing prescriptions.

Read more

OptumRx acquires specialty pharmacy Diplomat for $300 million

  • The deal follows the recent trend of industry consolidation and expands OptumRx’s specialty pharmacy and infusion service capabilities. 

Read more

Louisiana Department of Health reports positive results from “Netflix model” pricing of Hepatitis C drugs

  • Through the state’s Medicaid and Department of Corrections programs, more Louisiana residents have received Hepatitis C treatment in the first 75 days of the pricing plan’s implementation than in all of the fiscal year 2019.

Read more

Proposed rule describes procedures for the importation of prescription drugs

  • The federal government is accepting comments on the proposed rule, which would allow for the importation of certain prescription drugs from Canada.

Read more

CMS Office of the Actuary Releases 2018 National Health Expenditures

  • Retail prescription drug spending grew 2.5% in 2018 compared to 1.4% in 2017.
  • The increased growth rate was driven by non-price factors such as drug mix and utilization.

Read more

Senators Elizabeth Warren and Richard Blumenthal release report titled “Inaccessible Insulin: The Broken Promise of Eli Lilly’s Authorized Generic”

  • Report raises questions about the availability and consumer benefits of the newly introduced Humalog (insulin lispro) authorized generic.

Read more

Blue Cross Blue Shield of Massachusetts integrates PillPack into member app and website

  • Integration allows members easier utilization of the online pharmacy, decreasing reliance on traditional brick and mortar pharmacies.

Read more

CVS Health launches Transform Oncology Care program

  • The program uses genomic testing results at point-of-prescribing to match patients with appropriate treatments.
    • Testing results are also used to support the enrollment of patients into clinical trials.

Read more

Clinical Trials and Research

Jardiance (empagliflozin) produces negative results in EMPERIAL heart failure trial

  • In-class competitor Farxiga (dapagliflozin) is indicated to reduce risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.

Read more

BMJ study finds that up to 43% of antibiotic prescriptions were prescribed without an appropriate indication

  • Healthcare providers often inappropriately prescribe antibiotics for viral infections, contributing to antimicrobial resistance and wasteful spending.

Read more

Treatment Guidelines

CDC Vital Signs report outlines treatment target goals of proposed HIV treatment initiative

  • 18% of people at risk for HIV transmission have a PrEP prescription.
    • Target goal: 50%
  • 86% of people with HIV know they have it.
    • Target goal: 95%
  • 63% of people who know they have HIV have reached viral suppression.
    • Target goal: 95%

Read more

Leave a Reply

Your email address will not be published. Required fields are marked *